Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 6/2013

01-12-2013 | Cancer Prevention (J Cuzick, Section Editor)

Helicobacter pylori Eradication in the Prevention of Gastric Cancer: Are More Trials Needed?

Authors: Jin Young Park, David Forman, E. Robert Greenberg, Rolando Herrero

Published in: Current Oncology Reports | Issue 6/2013

Login to get access

Abstract

The incidence of gastric cancer has decreased in much of the world, but gastric cancer remains the second leading cause of cancer death globally, and the burden is growing in many countries in East Asia and Latin America. Chronic infection with Helicobacter pylori is the dominant cause of gastric cancer, and two recent randomized trials showed that H. pylori eradication significantly decreased gastric cancer risk. Population screening and treating individuals for H. pylori also appears to be cost-effective. Nevertheless, current clinical guidelines differ as to whether asymptomatic adults should be screened and treated for H. pylori, and no countries have yet implemented eradication programs. Some of this inaction may reflect lingering doubts about the effectiveness of H. pylori eradication in preventing gastric cancer, but there is also uncertainty about possible risks of mass antibiotic treatment and its impact on gut flora. Appropriately designed studies will help address these issues and hasten the implementation of population-wide prevention programs.
Literature
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRef
2.
Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet. 2012;380:1840–50.PubMedCrossRef
3.
Marugame T, Dongmei Q. Comparison of time trends in stomach cancer incidence (1973-1997) in East Asia, Europe and USA, from Cancer incidence in five continents vol. IV-VIII. Jpn J Clin Oncol. 2007;37:242–3.PubMedCrossRef
4.
Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al. Cancer incidence in five continents. Vol. IX. IARC Scientific Publications No. 160. Lyon: IARC; 2007.
5.
Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol. 2006;20:633–49.PubMedCrossRef
6.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, cancer incidence and mortality worldwide: IARC Cancer Base No. 10. 2010. Lyon: IARC; 2010. Available from http://​globocan.​iarc.​fr. Accessed 15 May 2013.
7.
Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. Lyon: IARC; 2010.
8.
Lochhead P, El-Omar EM. Helicobacter pylori infection and gastric cancer. Best Pract Res Clin Gastroenterol. 2007;21:281–97.PubMedCrossRef
9.
• Gonzalez CA, Megraud F, Buissonniere A, et al. Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project. Ann Oncol. 2012;23:1320–4. This study showed that using more accurate measures of H.p. infection in a cohort analysis resulted in estimates of risk of gastric cancer associated with H.p. that were threefold greater than those assessed using ELISA and that H.p. infection appeared to be a necessary cause of noncardia gastric cancer.
10.
IARC. Biological agents, IARC monographs, vol. 100B. Lyon: IARC; 2012.
11.
de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–15.PubMedCrossRef
12.
13.
Porras C, Nodora J, Sexton R, et al. Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). Cancer Causes Control. 2013;24:209–15.PubMedCrossRef
14.
Yim JY, Kim N, Choi SH, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter. 2007;12:333–40.PubMedCrossRef
15.
Oona M, Utt M, Nilsson I, Uibo O, Vorobjova T, Maaroos H. Helicobacter pylori infection in children in Estonia: decreasing seroprevalence during the 11-year period of profound socioeconomic changes. Helicobacter. 2004;9:233–41.PubMedCrossRef
16.
Leja M, Cine E, Rudzite D, et al. Prevalence of Helicobacter pylori infection and atrophic gastritis in Latvia. Eur J Gastroenterol Hepatol. 2012;24:1410–7.PubMedCrossRef
17.
18.
Rathbone M, Rathbone B. Helicobacter pylori and gastric cancer. In: Jankowski JAZ, editor. Inflammation and gastrointestinal cancers, Recent results in cancer research, vol. 185. Berlin: Springer; 2011.CrossRef
19.
Konturek PC, Konturek SJ, Brzozowski T. Helicobacter pylori infection in gastric cancerogenesis. J Physiol Pharmacol. 2009;60:3–21.PubMed
20.
Ohnishi N, Yuasa H, Tanaka S, et al. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci. 2008;105:1003–8.PubMedCrossRef
21.
Plummer M, van Doorn LJ, Franceschi S, et al. Helicobacter pylori cytotoxin-associated genotype and gastric precancerous lesions. J Natl Cancer Inst. 2007;99:1328–34.PubMedCrossRef
22.
23.
IARC. IARC monographs on the evaluation of carcinogenic risks to humans, Tobacco smoke and involuntary smoking, vol. 83. Lyon: IARC; 2004.
24.
Gonzalez CA, Agudo A. Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go. Int J Cancer. 2012;130:745–53.PubMedCrossRef
25.
World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington: American Institute for Cancer Research; 2007.
26.
Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC-Y. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2003;95:1784–91.PubMedCrossRef
27.
Yang P, Zhou Y, Chen B, et al. Aspirin use and the risk of gastric cancer: a meta-analysis. Dig Dis Sci. 2010;55:1533–9.PubMedCrossRef
28.
Zanghieri G, Gregorio CD, Sacchetti C, et al. Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. Cancer. 1990;66:2047–51.PubMedCrossRef
29.
Barber M, Murrell A, Ito Y, et al. Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. J Pathol. 2008;216:295–306.PubMedCrossRef
30.
Caldas C, Carneiro F, Lynch HT, et al. Familial gastric cancer: overview and guidelines for management. J Med Genet. 1999;36:873–80.PubMed
31.
Vogelaar I, van der Post R, Bisseling T, van Krieken JH, Ligtenberg M, Hoogerbrugge N. Familial gastric cancer: detection of a hereditary cause helps to understand its etiology. Hered Cancer Clin Pract. 2012;10:18.PubMedCrossRef
32.
El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000;404:398–402.PubMedCrossRef
33.
Persson C, Canedo P, Machado JC, El-Omar EM, Forman D. Polymorphisms in inflammatory response genes and their association with gastric cancer: a HuGE systematic review and meta-analyses. Am J Epidemiol. 2011;173:259–70.PubMedCrossRef
34.
Camargo MC, Murphy G, Koriyama C, et al. Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis. Br J Cancer. 2011;105:38–43.PubMedCrossRef
35.
36.
Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372:392–7.PubMedCrossRef
37.
•• Ma JL, Zhang L, Brown LM et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012;104:488–92. This study was the first trial with enough outcomes to provide a meaningful assessment of the effectiveness of H.p. eradication on cancer with the extended follow-up period.
38.
Wong BC-Y, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China. JAMA. 2004;291:187–94.PubMedCrossRef
39.
Wong VW, Chan FK. Eradication of H. pylori after endoscopic resection for early gastric cancer reduced risk for metachronous gastric cancer. ACP J Club. 2008;149:12.PubMed
40.
Loy CT, Irwig LM, Katelaris PH, Talley NJ. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol. 1996;91:1138–44.PubMed
41.
You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst. 2006;98:974–83.PubMedCrossRef
42.
Caselli M, Zullo A, Maconi G, et al. Cervia II working group report 2006: guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis. 2007;39:782–9.PubMedCrossRef
43.
Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808–25.PubMedCrossRef
44.
Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence consensus report. Gut. 2012;61:646–64.PubMedCrossRef
45.
Holloway K, Van Dijk L. The world medicines situation 2011: rational use of medicines. Geneva: WHO; 2011.
46.
Global Antibiotic Resistance Partnership- South Africa Working Group. Situation analysis: antibiotic use and resistance in South Africa. S Afr Med J. 2011;101:549–96.
47.
Global Antibiotic Resistance Partnership- Kenya Working Group. Situation analysis and recommendations: antibiotic use and resistance in Kenya. Washington: Center for Disease Dynamics, Economics & Policy; 2011.
48.
Wirtz VJ, Dreser A, Gonzales R. Trends in antibiotic utilization in eight Latin American countries, 1997-2007. Rev Panam Salud Publica. 2010;27:219–25.PubMedCrossRef
49.
Guzman-Blanco M, Casellas JM, Sader HS. Bacterial resistance to antimicrobial agents in Latin America. The giant is awakening. Infect Dis Clin N Am. 2000;14:67–81. viii.CrossRef
50.
Ganguly NK, Arora NK, Chandy SJ, et al. Rationalizing antibiotic use to limit antibiotic resistance in India. Indian J Med Res. 2011;134:281–94.PubMed
51.
52.
Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One. 2010;5:e9836.PubMedCrossRef
53.
Lampe JW. The Human Microbiome Project: getting to the guts of the matter in cancer epidemiology. Cancer Epidemiol Biomarkers Prev. 2008;17:2523–4.PubMedCrossRef
54.
Adamsson I, Nord CE, Lundquist P, Sjostedt S, Edlund C. Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. J Antimicrob Chemother. 1999;44:629–40.PubMedCrossRef
55.
Sjolund M, Wreiber K, Andersson DI, Blaser MJ, Engstrand L. Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann Intern Med. 2003;139:483–7.PubMedCrossRef
56.
Jakobsson H, Wreiber K, Fall K, Fjelstad B, Nyren O, Engstrand L. Macrolide resistance in the normal microbiota after Helicobacter pylori treatment. Scand J Infect Dis. 2007;39:757–63.PubMedCrossRef
57.
Ley RE, Lozupone CA, Hamady M, Knight R, Gordon JI. Worlds within worlds: evolution of the vertebrate gut microbiota. Nat Rev Microbiol. 2008;6:776–88.PubMedCrossRef
58.
Chow W, Blaser MJ, Blot WJ, et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res. 1998;58:588–90.PubMed
59.
Blaser MJ. Disappearing microbiota: Helicobacter pylori protection against esophageal adenocarcinoma. Cancer Prev Res. 2008;1:308–11.CrossRef
60.
Islami F, Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res. 2008;1:329–38.CrossRef
61.
Yamaji Y, Mitsushima T, Ikuma H, et al. Inverse background of Helicobacter pylori antibody and pepsinogen in reflux oesophagitis compared with gastric cancer: analysis of 5732 Japanese subjects. Gut. 2001;49:335–40.PubMedCrossRef
62.
Yaghoobi M, Farrokhyar F, Yuan Y, Hunt RH. Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-Analysis. Am J Gastroenterol. 2010;105:1007–13.PubMedCrossRef
63.
Azuma T, Suto H, Ito Y, et al. Eradication of Helicobacter pylori infection induces an increase in body mass index. Aliment Pharmacol Ther. 2002;16:240–4.PubMedCrossRef
64.
Furuta T, Shirai N, Xiao F, Takashima M, Hanai H. Effect of Helicobacter pylori infection and its eradication on nutrition. Aliment Pharmacol Ther. 2002;16:799–806.PubMedCrossRef
65.
Kamada T, Haruma K, Hata J, et al. The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. Aliment Pharmacol Ther. 2003;18:245–52.PubMedCrossRef
66.
Fujiwara Y, Higuchi K, Arafa UA, et al. Long-term effect of Helicobacter pylori eradication on quality of life, body mass index, and newly developed diseases in Japanese patients with peptic ulcer disease. Hepatogastroenterology. 2002;49:1298–302.PubMed
67.
Lane JA, Murray LJ, Harvey IM, Donovan JL, Nair P, Harvey RF. Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study. Aliment Pharmacol Ther. 2011;33:922–9.PubMedCrossRef
68.
Francois F, Roper J, Joseph N, et al. The effect of H. pylori eradication on meal-associated changes in plasma ghrelin and leptin. BMC Gastroenterol. 2011;11:37.PubMedCrossRef
69.
Zevit N, Balicer RD, Cohen HA, Karsh D, Niv Y, Shamir R. Inverse association between Helicobacter pylori and pediatric asthma in a high-prevalence population. Helicobacter. 2012;17:30–5.PubMedCrossRef
70.
Chen Y, Blaser MJ. Inverse associations of Helicobacter pylori with asthma and allergy. Arch Intern Med. 2007;167:821–7.PubMedCrossRef
71.
Perry S, de Jong BC, Solnick JV, et al. Infection with Helicobacter pylori is associated with protection against tuberculosis. PLoS One. 2010;5:e8804.PubMedCrossRef
72.
Areia M, Carvalho R, Cadime AT, Rocha GF, Dinis-Ribeiro M. Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. Helicobacter. 2013; 18:325–37.PubMedCrossRef
73.
Lee YC, Lin JT, Wu HM, et al. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:875–85.PubMedCrossRef
74.
Yeh JM, Kuntz KM, Ezzati M, Goldie SJ. Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer. 2009;124:157–66.PubMedCrossRef
75.
Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009; 24:1587–600.PubMedCrossRef
76.
Leung WK, Lin SR, Ching JY, To KF, Ng EK, Chan FK, Lau JY, Sung JJ. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut. 2004;53(9):1244–9.
77.
Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, Realpe JL, Malcom GT, Li D, Johnson WD, Mera R. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst. 2000; 6;92(23):1881–8.
78.
Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, Correa P. Long term follow up of patients treated for Helicobacter pylori infection. Gut. 2005;54(11):1536–40. Epub 2005 Jun 28.
Metadata
Title
Helicobacter pylori Eradication in the Prevention of Gastric Cancer: Are More Trials Needed?
Authors
Jin Young Park
David Forman
E. Robert Greenberg
Rolando Herrero
Publication date
01-12-2013
Publisher
Springer US
Published in
Current Oncology Reports / Issue 6/2013
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-013-0341-5

Other articles of this Issue 6/2013

Current Oncology Reports 6/2013 Go to the issue

Gynecologic Cancers (NS Reed, Section Editor)

Hormonal Treatment in Recurrent and Metastatic Gynaecological Cancers: A Review of the Current Literature

Invited Commentary

Latest Developments in the Biology and Management of Uveal Melanoma

Cancer Prevention (J Cuzick, Section Editor)

Role of Aspirin in Cancer Prevention

Gynecologic Cancers (NS Reed, Section Editor)

Clear Cell Carcinoma of Ovary and Uterus

Gynecologic Cancers (NS Reed, Section Editor)

A Review of Treatment of Uterine Leiomyosarcomas

Gynecologic Cancers (NS Reed, Section Editor)

Functional Imaging to Predict Tumor Response in Locally Advanced Cervical Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits